# Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

> **NCT05601440** · PHASE2 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 484 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** RP-6306
- **DRUG:** Gemcitabine
- **OTHER:** Observation
- **DRUG:** Niraparib
- **DRUG:** Fulvestrant
- **DRUG:** RP-3500
- **DRUG:** CFI-402257
- **DRUG:** CFI-400945
- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT05601440
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 484 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601440, "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT05601440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*